New late-breaking data presented at TCT confirmed that the first FDA-approved TTVR system for TR is associated with a much better quality of life than medical therapy alone after one year.
Didier Tchétché, MD, presents his team's pooled analysis on TAVR outcomes in women at TCT 2024.
New research presented at TCT combined data from the RHEIA and PARTNER 3 trials. “TAVR is a good option, and probably the best one, for an elderly woman," cardiologist Anna Sonia Petronio, MD, explained during the conference.
Interventional cardiologist Sanjit S. Jolly, MD, MSc, discusses results from the CLEAR SYNERGY (OASIS 9) clinical trial at TCT 2024.
Treating AMI patients with colchicine is not associated with better cardiovascular outcomes, according to new data presented at TCT. The drug did help with inflammation, but that was the only benefit researchers could identify.
The new organization, Heart Rhythm Advocates, will urge federal policymakers to pass legislation and support actions that have a positive impact on the future of electrophysiology.
EARLY TAVR lead investigator Philippe Généreux, MD, announces his team’s findings in front of a packed audience at TCT 2024. Attendees cheered and roared with excitement as he revealed the study’s primary outcomes, an early sign that interventional cardiologists have been anticipating these results for quite some time.
Attendees cheered as lead investigator Philippe Généreux, MD, shared his team's findings at TCT 2024. “A major reset in our approach to severe asymptomatic AS is now warranted,” one veteran cardiologist said about the data. “The concept of watchful waiting is no longer appropriate."
